Evidence map›Paper›PMID 32765497›Full record

ArticleFrontiers in immunology2020

Distinct Single Cell Gene Expression in Peripheral Blood Monocytes Correlates With Tumor Necrosis Factor Inhibitor Treatment Response Groups Defined by Type I Interferon in Rheumatoid Arthritis.

Theresa L Wampler Muskardin, Wei Fan, Zhongbo Jin, Mark A Jensen, Jessica M Dorschner, Yogita Ghodke-Puranik, Betty Dicke, Danielle Vsetecka, Kerry Wright, Thomas Mason and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. CD4Clinical and experimental immunology · 2021
    Trial
  2. Review
  3. Role of IFN-α in Rheumatoid Arthritis.Current rheumatology reports · 2024
    Review
  4. Article
  5. Review
  6. New insights into the pathogenesis and management of rheumatoid arthritis.Chronic diseases and translational medicine · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Theresa L Wampler MuskardinDepartment of Medicine, Colton Center for Autoimmunity, New York University School of Medicine, New York, NY, United States.
Wei FanDepartment of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhongbo JinDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, United States.
Mark A JensenDepartment of Medicine, Colton Center for Autoimmunity, New York University School of Medicine, New York, NY, United States.
Jessica M DorschnerDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Yogita Ghodke-PuranikDepartment of Medicine, Colton Center for Autoimmunity, New York University School of Medicine, New York, NY, United States.
Betty DickeDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Danielle VseteckaDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Kerry WrightDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Thomas MasonDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Scott PersellinDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Clement J MichetDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
John M DavisDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Eric MattesonDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Timothy B NiewoldDepartment of Medicine, Colton Center for Autoimmunity, New York University School of Medicine, New York, NY, United States.
Mayo Clinic in Arizona · USNew York University · USShanghai Jiao Tong University · CNUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we demonstrated in test and validation cohorts that type I IFN (T1IFN) activity can predict non-response to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). In this study, we examine the biology of non-classical and classical monocytes from RA patients defined by their pre-biologic treatment T1IFN activity. We compared single cell gene expression in purified classical (CL,

Indexed as

AdultAgedAntirheumatic AgentsArthritis, RheumatoidFemaleHumansInterferon Type IMaleMiddle AgedMonocytesSingle-Cell AnalysisTranscriptomeTumor Necrosis Factor InhibitorsAntirheumatic AgentsInterferon Type ITumor Necrosis Factor Inhibitorsinterferon-alphainterferon-betajanus kinase 1monocyterheumatoid arthritissingle celltumor necrosis factor-alphatype I interferon

Identifiers

PMID32765497
PMCPMC7378891
OpenAlexW3042709512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.